Compare Main Street Capital Corporation (MAIN) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Main Street Capital Corporation vs Medpace Holdings Inc — how do they compare? Main Street Capital Corporation trades at $54.6 (market cap $5.08B), while Medpace Holdings Inc trades at $530 (market cap $15.08B). The key difference: Medpace Holdings Inc is far larger — about 3× Main Street Capital Corporation's market cap, and Main Street Capital Corporation pays a 8.02% dividend while Medpace Holdings Inc pays none. Which is the better fit depends on your goals.
| MAIN | MEDP | |
|---|---|---|
Market Cap | $5.08B | $15.08B |
Sector | Financials | Technology |
52-Week High | $67.54 | $620.59 |
52-Week Low | $49.63 | $308.88 |
Dividend Yield | 8.02% | — |
Enterprise Value | — | $14.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Main Street Capital (MAIN) trades at $54.19, down 2.13% today, with a bullish technical signal from moving averages. The stock shows strong profitability with an 81.08% net income margin and a P/E of 11.49, below industry averages. Recent earnings have been mixed, with Q4 2025 beating expectations but Q1 2026 missing. The company maintains a consistent dividend history, with recent payouts of $0.27-$0.30 per share, supporting income-focused investors.
Outlook remains cautious with 78.57% of analysts rating Hold, citing potential earnings softness. The consensus price target is $57.75, offering modest upside. Key risks include declining revenue projections for 2026 and negative operating cash flow. MAIN's premium valuation relative to book value is justified by cost advantages, but investors should monitor earnings sustainability amid economic headwinds.
MEDP trades at $527.93, down 1.82% on the day, with a neutral technical signal and mixed oscillators. The stock shows strong profitability with a 17.19% net margin and 77.25% ROE, though valuations are elevated with a P/E of 33.22. Recent quarters have consistently beaten EPS estimates, but a class action lawsuit filed in June 2026 adds uncertainty. Revenue is projected to grow to $2.7B in 2026, while cash flow trends improve from negative to positive net cash flow.
The outlook is cautious due to high valuation and legal overhangs, but fundamental strength in earnings and backlog quality provides support. Analyst consensus is mixed with a $497 price target below current levels, indicating limited near-term upside. Key risks include lawsuit outcomes and competitive pressures in the CRO sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Main Street Capital Corporation
Main Street Capital Corp is an investment firm engaged in providing customized debt and equity financing to lower middle market companies and debt capital to middle market companies. The investment portfolio of the company is typically made to support management buyouts, recapitalizations, growth financings, refinancings and acquisitions of companies that operate in diverse industry sectors. The group invests in secured debt investments, equity investments, warrants and other securities of the lower middle market and middle market companies based in the US. Business is functioned through the U.S region and it derives the majority of the income from the source of fee, commission, and interest.
Read more on MAIN →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
